ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $12.50 Average PT from Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $12.50.

ALXO has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research note on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of ALX Oncology in a research note on Tuesday, August 13th. UBS Group cut their price target on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co acquired a new position in shares of ALX Oncology in the 1st quarter valued at $27,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after acquiring an additional 5,200 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of ALX Oncology by 33.6% during the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after purchasing an additional 6,888 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology during the second quarter worth about $63,000. Finally, GSA Capital Partners LLP purchased a new stake in shares of ALX Oncology in the 3rd quarter valued at about $88,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Trading Down 2.0 %

Shares of ALXO stock opened at $1.48 on Thursday. ALX Oncology has a fifty-two week low of $1.19 and a fifty-two week high of $17.83. The company has a 50 day moving average price of $1.54 and a 200 day moving average price of $4.45. The stock has a market capitalization of $78.06 million, a P/E ratio of -0.50 and a beta of 1.03. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.